Since galectin-1 and galectin-3 are implicated in the increased angiogenesis that drives tumor proliferation and expansion, monoclonal antibodies against these galectins could help mitigate the VEGF pathway and slow cancer progression [47]. This evidence concerns the gene LGALS3 and cancer.